But it's nice to be able to have the opportunity to update everybody on what's going on the Regeneron because the last year has really been a year of transformation for us in many ways.

What to watch at ASCO Regeneron Pharmaceuticals Inc (NASDAQ:REGN), perhaps best known for its highly successful wet age-related macular degeneration drug Eylea, released two promising abstracts for ASCO on monoclonal antibodies with potential ...

(RTTNews.com) - Regeneron Pharmaceuticals Inc. ( REGN ) reported first quarter net income of $0.90 per share Friday morning, up from $0.11 per share in the prior year.

Sanofi (NYSE: SNY) and partner Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) recently announced that they started enrolling patients for two phase III trials (SARIL-RA COMPARE and SARIL-RA ASCERTAIN) on their rheumatoid arthritis (RA) candidate, ...

PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully ...

(By Mani) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares are on the bullish territory on Eylea fundamentals, which continue to improve with long-term sustainability of ophthalmology related revenues.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) investors should be aware of an increase in enthusiasm from smart money in recent months.

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at ...

Dow Jones Newswires. Regeneron Pharmaceuticals Inc.'s (REGN) stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too.

New York, NY -- (SBWIRE) -- 05/08/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Biogen Idec Inc.